Last $0.55 USD
Change Today -0.05 / -8.33%
Volume 292.3K
NSPR On Other Exchanges
As of 4:15 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

inspiremd inc (NSPR) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $3.69
52 Week Low
02/26/15 - $0.54
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INSPIREMD INC (NSPR)

Related News

No related news articles were found.

inspiremd inc (NSPR) Related Businessweek News

No Related Businessweek News Found

inspiremd inc (NSPR) Details

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MGuard stent platform technology. Its MGuard stent is an embolic protection device based on a protective sleeve, which is constructed out of an ultra-thin polymer mesh and wrapped around the stent. The company markets its products for use primarily in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack), and saphenous vein graft coronary interventions (bypass surgery). It serves various customers in Europe, Latin America, Asia, Israel, and internationally. InspireMD, Inc. is headquartered in Boston, Massachusetts.

71 Employees
Last Reported Date: 09/25/14

inspiremd inc (NSPR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $500.0K
Chief Financial Officer, Chief Administrative...
Total Annual Compensation: $142.3K
Chief Technology Officer, Chief Technical Off...
Total Annual Compensation: $136.3K
Compensation as of Fiscal Year 2013.

inspiremd inc (NSPR) Key Developments

InspireMD, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 10:40 AM

InspireMD, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 10:40 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Alan W. Milinazzo, Chief Executive Officer, President and Director.

InspireMD Receives Non-Compliance Notice From NYSE MKT

InspireMD, Inc. announced the receipt of a notice indicating that InspireMD does not meet certain of the NYSE MKT LLC's continued listing standards as set forth in Part 10 of the NYSE MKT Company Guide. The Exchange's notice has no immediate effect on the listing of the Company's common stock on the Exchange. The Company's management is reviewing its options to address the deficiency and expects to submit a compliance plan on or before the deadline set by the Exchange. On January 20, 2015, InspireMD received a letter from the NYSE MKT notifying InspireMD that it is not in compliance with Section 1003(a)(i), Section 1003(a)(ii) and Section 1003(a)(iii) of the Company Guide because it reported stockholders' equity of less than $2 million, $4 million, and $6 million respectively, as of September 30, 2014 and had net losses in its five most recent fiscal years ended June 30, 2013. In addition, the NYSE MKT indicated that InspireMD is not in compliance with Section 1003(a)(iv) of the Company Guide because it has sustained losses that are substantial in relation to its overall operations or its existing financial resources, or its financial condition has become impaired such that it appears questionable, in the opinion of the NYSE MKT, as to whether InspireMD will be able to continue operations and/or meet its obligations as they mature. As a result, InspireMD has become subject to the procedures and requirements of Section 1009 of the Company Guide. In order to maintain its listing on the Exchange, InspireMD must submit a plan of compliance to the NYSE MKT by February 19, 2015 addressing how it intends to regain compliance with Sections 1003(a)(i), 1003(a)(ii) and 1003 (a)(iii) of the Company Guide by July 20, 2016 and Section 1003(a)(iv) of the Company Guide by June 1, 2015.

InspireMD Announces Important Clinical Data from MASTER and CARENET Trials

InspireMD, Inc. announced results from two important clinical trials. 30 day results from the MASTER II trial which enrolled 310 of a planned 1,114 patients was presented at a major cardiology congress in Israel. The trial was suspended in October 2014 as a result of a corporate shift in strategy to a next generation MGuard drug eluting stent (DES) platform. The Company also announced ipsilateral DW-MRI results from the CARENET Trial for the CGuard system which successfully completed enrollment in July. MASTER II was a global clinical trial conducted under a U.S. Food and Drug Agency (FDA) Investigational Device Exemption (IDE) and was intended for U.S. registration of the MGuard Prime coronary EPS for use in patients presenting with STEMI (ST-segment Elevated Myocardial Infarction). The MASTER II trial was designed to show superiority of ST segment resolution 60-90 minutes post procedure as well non-inferiority in all-cause death or recurrent target vessel myocardial infarction. While the trial was halted well short of the planned enrollment, the Company elected to unblind the data and present the results on behalf of the study investigators.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NSPR:US $0.55 USD -0.05

NSPR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $47.09 USD -0.13
Boston Scientific Corp $16.76 USD -0.30
Johnson & Johnson $102.34 USD -0.88
Medtronic PLC $78.03 USD -0.80
Sorin SpA €2.90 EUR +0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation NSPR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSPIREMD INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at